Throwing the kitchen sink at melanoma drug development
暂无分享,去创建一个
[1] K. Flaherty,et al. Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. , 2012 .
[2] P. Sorger,et al. Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.
[3] K. Flaherty,et al. From genes to drugs: targeted strategies for melanoma , 2012, Nature Reviews Cancer.
[4] T. Fennell,et al. Melanoma genome sequencing reveals frequent PREX2 mutations , 2012, Nature.
[5] S. Davis,et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.